[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Cancer Monoclonal Antibodies Market & Pipeline Insight

September 2014 | 1400 pages | ID: G6F4B76C7EAEN
Kuick Research

US$ 2,400.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharma companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system so as to develop more efficient mAbs.

A significant amount of research is being carried out currently to improve the level of potency of monoclonal antibodies. Consequently, a relatively new approach has been indentified in which the precision of targeting molecules would be combined with the proved killing power of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular carriers, mostly monoclonal antibodies. However, still a lot of work needs to be done in this arena.

Though the monoclonal antibodies have already emerged as significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.

Additionally, the pharma companies are also researching on ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body’s immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies. The future of mAbs for cancer continues to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human cells there is still significant work which needs to be done.

“Global Cancer Monoclonal Antibodies Market & Pipeline Insight” Report highlights:
  • Cancer Monoclonal Antibodies Market Overview
  • Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook
  • Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
  • Cancer Monoclonal Antibodies in Pipeline: 605
  • Majority Cancer Monoclonal Antibodies Preclinical Phase: 258
  • Marketed Cancer Monoclonal Antibodies: 34
  • Cancer Monoclonal Antibodies Patent Analysis


1. INTRODUCTION TO MONOCLONAL ANTIBODIES

1.1 History of Development of Monoclonal Antibodies
1.2 Working of Monoclonal Antibodies

2. TYPES OF MONOCLONAL ANTIBODIES

2.1 Naked Monoclonal Antibodies
2.2 Conjugated Monoclonal Antibodies
  2.2.1 Radiolabeled Antibodies
  2.2.2 Chemolabeled Antibodies
  2.2.3 Immunotoxins

3. MECHANISMS OF MONOCLONAL ANTIBODIES

3.1 Tumor Antigens as Targets of Antibodies
3.2 Development of Antibodies for Clinical Purposes
3.3 Complement Dependent Cytotoxicity (CDC)
3.4 Signal Transduction Changes

4. NEED FOR MONOCLONAL ANTIBODIES FOR CANCER TREATMENT

5. CANCER MONOCLONAL ANTIBODIES MARKET OVERVIEW

5.1 Current Market Scenario
5.2 Clinical Pipeline Insight

6. CANCER MONOCLONAL ANTIBODIES MARKET DYNAMICS

6.1 Favorable Parameters
6.2 Challenges
6.3 Future Growth Outlook

7. CANCER MONOCLONAL ANTIBODIES PIPELINE BY PHASE, INDICATION, COMPANY & COUNTRY

7.1 Phase Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase II/III
7.9 Phase III
7.10 Preregistration
7.11 Registered

8. MARKETED CANCER MONOCLONAL ANTIBODIES BY INDICATION, COMPANY & COUNTRY

9. SUSPENDED & DISCONTINUED MONOCLONAL ANTIBODIES PIPELINE BY PHASE, INDICATION, COMPANY & COUNTRY

9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended

10. COMPETITIVE LANDSCAPE

10.1 Abbvie
10.2 Amgen
10.3 Bayer HealthCare
10.4 Biogen Idec
10.5 Eli Lilly
10.6 Genmab
10.7 Gilead Sciences
10.8 GlaxoSmithKline
10.9 Novartis
10.10 Pfizer
10.11 Roche
10.12 Seattle Genetics

LIST OF FIGURES

Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 2-1: Types of Monoclonal Antibodies
Figure 5-1: Global Biologics Market Classification
Figure 5-2: Share of Monoclonal Antibodies in Biologics Market (%), 2013 & 2020
Figure 5-3: Global Market for Monoclonal Antibodies (US$ Billion), 2013-2020
Figure 5-4: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2014
Figure 5-5: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2014
Figure 5-6: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-7: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
Figure 5-8: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-9: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
Figure 5-10: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
Figure 5-11: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014


More Publications